The "Drug Analysis: DCVAC/PCa" drug pipelines has been added to ResearchAndMarkets.com's offering.
DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells, which can then recognize and destroy prostate cancer tumor cells.
Key Topics Covered:
List of Figures
Figure 1: DCVAC/PCa for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 3: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: DCVAC/PCa drug profile
Table 2: DCVAC/PCa Phase III trial in prostate cancer
Table 3: DCVAC/PCa Phase I/II data in prostate cancer
Table 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country M, 2017-26
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/slm633/2018_dcvacpca?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20180221006160/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.